Innovative Suite Combines Live Medical Imaging, 3D Anatomy Visualization, And Advanced Imaging Technologies With Remote Collaboration Capabilities
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
| 9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
| 9/9/2024 | $90.00 | Neutral | JP Morgan |
| 8/6/2024 | $100.00 | Buy | Stifel |
| 5/30/2024 | $87.00 | Neutral | Goldman |
| 2/15/2024 | $100.00 | Buy | HSBC Securities |
| 2/12/2024 | $66.00 → $88.00 | Sell → Neutral | UBS |
| 11/30/2023 | $80.00 | Hold | Jefferies |
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.
Published in the Journal of Clinical Anesthesia, results from the two-phase, 250 patient pilot study show clinicians found a majority (82%) of the alarms from the wireless and wearable Portrait Mobile monitoring solution to be informative or useful to optimize patient care in medical-surgical units.1 Study findings suggest that continuous monitoring helps provide critical information to clinicians, enabling them to intervene effectively before a patient deteriorates. Undetected patient deterioration, particularly post-surgery, can lead to hazardous yet preventable consequences, with 30-day mortality after surgery representing the third leading cause of death globally.2 GE HealthCa
New MRI technology aims to advance neuroimaging and biomarker research GE HealthCare (NASDAQ:GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions. The FDA clearance of SIGNA MAGNUS underscores the advances made by GE HealthCare in neuroimaging. It features an innovative asymmetrical, high-efficiency, head-only gradient coil design, which achieves higher gradient performance due to its reduced inner diameter, spe
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
424B3 - GE HealthCare Technologies Inc. (0001932393) (Filer)
GE HealthCare (NASDAQ:GEHC) today announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC's (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for total consideration of approximately $51 million. Intelligent Ultrasound is a leader in integrated AI-driven image analysis tools designed to make ultrasound smarter and more efficient. GE HealthCare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease-of-use for the benefit of clinicians and patients.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BEARISH 07/19/24 $28.00 $72.8K 28.1K 2.7K MRK CALL SWEEP BEARISH 07/19/24 $140.00 $78.
Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.
Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range GE HealthCare (NASDAQ:GEHC) today repor
GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions inno
UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously
BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00
JP Morgan initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $90.00
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)